the new drug used for allergic reactions, neffy, uses the same spray device as narcan, but instead of using naloxone, the spray administers epinephrine to help reverse the life-threatening effects of an allergic reaction.
approving the spray to address treatment avoidance
the spray has been approved for use in adults and children as long as they weigh over 66 pounds. it’s single-use and is designed to reduce the need for needles while allowing people to feel safe to be out in the world when they have severe allergies.
dr. kelly stone, associate director of the division of pulmonology, allergy, and critical care in the fda’s centre for drug evaluation and research, noted in a news release that “some people, particularly children, may delay or avoid treatment due to fear of injections.”
because of this avoidance, many people are put at a heightened risk of worsened outcomes because delaying treatment while in anaphylaxis can mean the difference between life and death.
the data that led to the approval
to ensure the new nasal spray method would work as well for allergic reactions as it does for those with opioid overdoses, the drug was tested in both children and adults. when measured against injected epinephrine, the results showed that the nasal spray was as viable as the injection, giving researchers the data they needed to bring it to the fda for approval.